-
Je něco špatně v tomto záznamu ?
Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
H. Olbertova, K. Plevova, S. Pavlova, J. Malcikova, J. Kotaskova, K. Stranska, M. Spunarova, M. Trbusek, V. Navrkalova, B. Dvorackova, N. Tom, K. Pal, M. Jarosova, Y. Brychtova, A. Panovska, M. Doubek, S. Pospisilova
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
MH-CZ RVO 65269705
Ministerstvo Zdravotnictví Ceské Republiky
AZV NU21-08-00237
Ministerstvo Zdravotnictví Ceské Republiky
AZV NV19-03-00091
Ministerstvo Zdravotnictví Ceské Republiky
GACR 19-15737S
Grantová Agentura České Republiky
GACR 19-11299S
Grantová Agentura České Republiky
LM2018132
Technologická Agentura České Republiky
LM2018133
Technologická Agentura České Republiky
CZ.02.1.01/0.0/0.0/18_046/0015515
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
BioMedCentral
od 2001-01-12
BioMedCentral Open Access
od 2001
Directory of Open Access Journals
od 2001
Free Medical Journals
od 2001
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Medline Complete (EBSCOhost)
od 2001-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
Springer Nature OA/Free Journals
od 2001-12-01
- MeSH
- chronická lymfatická leukemie genetika MeSH
- klonální evoluce genetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádorový supresorový protein p53 genetika MeSH
- protoonkogenní proteiny c-bcr metabolismus MeSH
- signální transdukce MeSH
- telomerasa genetika MeSH
- telomery ultrastruktura MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Telomeres are protective structures at chromosome ends which shorten gradually with increasing age. In chronic lymphocytic leukemia (CLL), short telomeres have been associated with unfavorable disease outcome, but the link between clonal evolution and telomere shortening remains unresolved. METHODS: We investigated relative telomere length (RTL) in a well-characterized cohort of 198 CLL patients by qPCR and focused in detail on a subgroup 26 patients who underwent clonal evolution of TP53 mutations (evolTP53). In the evolTP53 subgroup we explored factors influencing clonal evolution and corresponding changes in telomere length through measurements of telomerase expression, lymphocyte doubling time, and BCR signaling activity. RESULTS: At baseline, RTL of the evolTP53 patients was scattered across the entire RTL spectrum observed in our CLL cohort. RTL changed in the follow-up samples of 16/26 (62%) evolTP53 cases, inclining to reach intermediate RTL values, i.e., longer telomeres shortened compared to baseline while shorter ones prolonged. For the first time we show that TP53 clonal shifts are linked to RTL change, including unexpected RTL prolongation. We further investigated parameters associated with RTL changes. Unstable telomeres were significantly more frequent among younger patients (P = 0.032). Shorter telomeres were associated with decreased activity of the B-cell receptor signaling components p-ERK1/2, p-ZAP-70/SYK, and p-NFκB (P = 0.04, P = 0.01, and P = 0.02, respectively). CONCLUSIONS: Our study revealed that changes of telomere length reflect evolution in leukemic subclone proportion, and are associated with specific clinico-biological features of the explored cohort.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011067
- 003
- CZ-PrNML
- 005
- 20220506130417.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12885-022-09221-z $2 doi
- 035 __
- $a (PubMed)35114947
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Olbertova, Helena $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 245 10
- $a Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes / $c H. Olbertova, K. Plevova, S. Pavlova, J. Malcikova, J. Kotaskova, K. Stranska, M. Spunarova, M. Trbusek, V. Navrkalova, B. Dvorackova, N. Tom, K. Pal, M. Jarosova, Y. Brychtova, A. Panovska, M. Doubek, S. Pospisilova
- 520 9_
- $a BACKGROUND: Telomeres are protective structures at chromosome ends which shorten gradually with increasing age. In chronic lymphocytic leukemia (CLL), short telomeres have been associated with unfavorable disease outcome, but the link between clonal evolution and telomere shortening remains unresolved. METHODS: We investigated relative telomere length (RTL) in a well-characterized cohort of 198 CLL patients by qPCR and focused in detail on a subgroup 26 patients who underwent clonal evolution of TP53 mutations (evolTP53). In the evolTP53 subgroup we explored factors influencing clonal evolution and corresponding changes in telomere length through measurements of telomerase expression, lymphocyte doubling time, and BCR signaling activity. RESULTS: At baseline, RTL of the evolTP53 patients was scattered across the entire RTL spectrum observed in our CLL cohort. RTL changed in the follow-up samples of 16/26 (62%) evolTP53 cases, inclining to reach intermediate RTL values, i.e., longer telomeres shortened compared to baseline while shorter ones prolonged. For the first time we show that TP53 clonal shifts are linked to RTL change, including unexpected RTL prolongation. We further investigated parameters associated with RTL changes. Unstable telomeres were significantly more frequent among younger patients (P = 0.032). Shorter telomeres were associated with decreased activity of the B-cell receptor signaling components p-ERK1/2, p-ZAP-70/SYK, and p-NFκB (P = 0.04, P = 0.01, and P = 0.02, respectively). CONCLUSIONS: Our study revealed that changes of telomere length reflect evolution in leukemic subclone proportion, and are associated with specific clinico-biological features of the explored cohort.
- 650 _2
- $a klonální evoluce $x genetika $7 D060965
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x genetika $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a protoonkogenní proteiny c-bcr $x metabolismus $7 D051562
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a telomerasa $x genetika $7 D019098
- 650 _2
- $a telomery $x ultrastruktura $7 D016615
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Plevova, Karla $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Pavlova, Sarka $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Malcikova, Jitka $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Kotaskova, Jana $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Stranska, Kamila $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Spunarova, Michaela $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Trbusek, Martin $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Navrkalova, Veronika $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Dvorackova, Barbara $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Tom, Nikola $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic
- 700 1_
- $a Pal, Karol $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic
- 700 1_
- $a Jarosova, Marie $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Brychtova, Yvona $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Panovska, Anna $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Doubek, Michael $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Pospisilova, Sarka $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz $1 https://orcid.org/0000000171362680
- 773 0_
- $w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 22, č. 1 (2022), s. 137
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35114947 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130409 $b ABA008
- 999 __
- $a ok $b bmc $g 1788921 $s 1162265
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 22 $c 1 $d 137 $e 20220203 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
- GRA __
- $a MH-CZ RVO 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a AZV NU21-08-00237 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a AZV NV19-03-00091 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a GACR 19-15737S $p Grantová Agentura České Republiky
- GRA __
- $a GACR 19-11299S $p Grantová Agentura České Republiky
- GRA __
- $a LM2018132 $p Technologická Agentura České Republiky
- GRA __
- $a LM2018133 $p Technologická Agentura České Republiky
- GRA __
- $a CZ.02.1.01/0.0/0.0/18_046/0015515 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20220425